Milk allergy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:35:15 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Milk allergy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Omeprazole and Cow’s Milk-Free Diet for Treating Gastroesophageal Reflux Disease in Infants Under 1 Year https://clinicaltrials.eu/trial/study-on-omeprazole-and-cows-milk-free-diet-for-treating-gastroesophageal-reflux-disease-in-infants-under-1-year/ Wed, 29 Apr 2026 14:58:19 +0000 https://clinicaltrials.eu/trial/study-on-omeprazole-and-cows-milk-free-diet-for-treating-gastroesophageal-reflux-disease-in-infants-under-1-year/ This clinical trial is focused on studying the treatment of Gastroesophageal Reflux Disease (GERD) in infants. GERD is a condition where stomach acid frequently flows back into the tube connecting the mouth and stomach, causing discomfort. The study will also consider infants with a cow’s milk allergy, which is an allergic reaction to proteins found in cow’s milk. The treatment being tested is a medication called Omeprazole, which is a type of drug known as a proton pump inhibitor. This medication is designed to reduce the amount of acid produced in the stomach. The study will compare the effects of Omeprazole with a placebo, which is a substance with no active medication, to see how effective Omeprazole is in treating GERD in infants.

The purpose of the study is to investigate how well a cow’s milk-free diet or Omeprazole works in reducing the symptoms of GERD in infants under one year of age. During the study, parents will be asked to record the number of reflux episodes their child experiences each week using an app. This will help researchers understand how the treatment affects the frequency of reflux episodes. The study will last for several weeks, and parents will be required to monitor and report any changes in their child’s symptoms, such as crying, discomfort, or feeding difficulties.

Throughout the study, the safety and any side effects of Omeprazole will be closely monitored. Parents will report any adverse events, such as stomach pain or nausea, that their child may experience. Additionally, the study will assess changes in the child’s weight and any signs of improvement in symptoms related to GERD and cow’s milk allergy. The trial aims to provide valuable information on the effectiveness of Omeprazole and dietary changes in managing GERD in infants.

]]> Study on the Safety and Effectiveness of Low-Dose Oral Immunotherapy with Omalizumab for Children with Severe Cow’s Milk Allergy https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-low-dose-oral-immunotherapy-with-omalizumab-for-children-with-severe-cows-milk-allergy/ Wed, 29 Apr 2026 14:26:55 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-low-dose-oral-immunotherapy-with-omalizumab-for-children-with-severe-cows-milk-allergy/ This clinical trial is focused on children with a severe allergy to cow’s milk, specifically an IgE-mediated cow’s milk allergy. The study is investigating the use of a treatment called Omalizumab, which is a medication given as an injection. Omalizumab is known to help manage allergies by targeting a specific protein in the body that plays a role in allergic reactions. The study will also involve a process called oral immunotherapy, where small amounts of milk are gradually introduced to the child’s diet to help build tolerance.

The purpose of the study is to analyze the safety and effectiveness of combining low-dose oral immunotherapy with Omalizumab in children with severe cow’s milk allergy. During the study, participants will receive injections of Omalizumab and will be exposed to small amounts of milk under medical supervision. The study will monitor how well the children tolerate the milk and whether the treatment helps reduce allergic reactions over time.

The study will last for a period of up to 18 months. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and to assess the effectiveness of the treatment. The goal is to see if the combination of Omalizumab and oral immunotherapy can help children with severe cow’s milk allergy tolerate milk better and experience fewer allergic reactions.

]]>